Zenith Pharma Group plc, a FTSE 250 life-sciences company headquartered in Cambridge with manufacturing subsidiaries in Ireland and Singapore, earns GBP 340m of group revenue. Its Irish subsidiary, which holds the group's principal patents, charges the UK parent GBP 62m in royalties annually — a figure HMRC's Large Business directorate considers far in excess of what an independent licensor would charge. The resulting transfer pricing enquiry carries a potential GBP 28m additional tax liability plus interest and penalties. The group's head of tax must demonstrate arm's-length pricing or negotiate a bilateral Advance Pricing Agreement before the next compliance deadline.
TIOPA 2010 Part 4 requires that profits arising from transactions between connected UK and non-UK persons are calculated as if those transactions had been made on arm's-length terms — the terms that independent parties in comparable circumstances would have agreed. Where actual terms differ from arm's-length terms and a UK person's profits are reduced, an arm's-length adjustment restores those profits. The 2022 OECD Transfer Pricing Guidelines are the primary interpretive authority for UK practitioners and HMRC's Large Business directorate.
Arm's-Length Principle (TIOPA 2010 s.147)
The statutory requirement that intra-group transactions are priced as if between independent parties at arm's length. Where actual terms depart from arm's-length terms and reduce UK taxable profits, HMRC may make an arm's-length adjustment under TIOPA 2010 s.147. The OECD Transfer Pricing Guidelines (2022) are expressly adopted by HMRC as interpretive guidance.
Country-by-Country Reporting (CbCR — OECD BEPS Action 13)
UK-parented multinational groups with consolidated annual revenue of GBP 586m (EUR 750m equivalent) or above must file a CbCR with HMRC annually within 12 months of the reporting fiscal year end, disclosing revenues, profits, tax paid, headcount, and stated capital by jurisdiction. HMRC exchanges CbCR data with treaty partners through automatic exchange of information. From 2025, public CbCR disclosure obligations under the EU Accounting Directive apply to UK groups with EU subsidiaries.
Connected parties for TIOPA 2010 purposes include a company and any person with a 40% or more participation interest, or two companies where a third person has a 40% or more interest in each. Participation interest covers equity stakes, voting rights, and economic rights. Most intra-group transactions — goods, services, IP licences, intra-group loans, and management charges — fall within Part 4 scope, and the burden of proof rests on the taxpayer to demonstrate arm's-length pricing.
Advance Pricing Agreement (APA — HMRC INTM422000)
An APA is a binding agreement between a taxpayer and one or more tax authorities specifying the transfer pricing methodology to apply to designated transactions for a fixed period (typically three to five years). A unilateral APA covers only HMRC; a bilateral APA involves HMRC and one foreign authority via a Mutual Agreement Procedure; a multilateral APA covers three or more jurisdictions. APAs provide certainty and eliminate double taxation risk but require significant investment in preparation (typically GBP 50,000 to GBP 200,000 in adviser fees) and 12 to 36 months of negotiation.
| TP Method | Best Used For | HMRC / OECD Preference |
|---|---|---|
| Comparable Uncontrolled Price (CUP) | Commodity transactions, loans, royalties with market rates | Preferred if reliable comparables exist |
| Resale Price Method (RPM) | Distribution of finished goods | Strong where distributor adds little value |
| Cost-Plus Method | Contract manufacturing, intra-group services | Acceptable where cost base is stable |
| TNMM | Routine functions (services, routine manufacturing) | Most common for HMRC Large Business TP cases (~70%) |
| Profit Split | Unique intangibles, highly integrated operations | Required where no reliable comparables available |
The Transactional Net Margin Method (TNMM) compares the net profit margin earned by the tested party against comparable independent companies. Selecting an appropriate comparable set requires searching public databases (Bureau van Dijk Orbis, TP Catalyst) and applying statistical filters: same industry, comparable functions, assets and risks, and a minimum number of uncontrolled comparables. The interquartile range of results is the arm's-length range; if the tested party falls below the median, HMRC typically adjusts to the median on enquiry.
UK transfer pricing documentation requirements are broadly aligned with OECD BEPS Action 13 but do not mandate automatic filing of the Master File or Local File with HMRC. They must be prepared contemporaneously and produced on request within 30 days. HMRC's CJRS scheme and HMRC's Large Business Service conduct dedicated TP specialist reviews; smaller businesses may also face enquiries under HMRC's mid-size compliance units. The practical threshold for HMRC enquiry focus is groups with consolidated turnover above GBP 50m.
| Document | UK Threshold | Key Content | Deadline |
|---|---|---|---|
| Transfer Pricing Documentation (TIOPA 2010 s.162) | All connected-party transactions potentially in scope; practical threshold for HMRC enquiry focus: groups with > GBP 50m turnover | Functional analysis, method selection, benchmarking study | Must exist before filing the return (contemporaneous) |
| Master File (OECD BEPS Action 13) | Consolidated group revenue >= GBP 586m | Group overview, value chain, IP ownership, financing | 12 months after fiscal year end |
| Local File (OECD BEPS Action 13) | Consolidated group revenue >= GBP 586m | Entity-level transactions, FAR, benchmarks | 12 months after fiscal year end |
| Country-by-Country Report (CbCR) | Consolidated group revenue >= GBP 586m | Revenue, profit, tax, headcount per jurisdiction | 12 months after fiscal year end (HMRC automatic exchange) |
| Mechanism | Nature | Duration | Cost | Key Benefit |
|---|---|---|---|---|
| MAP (Mutual Agreement Procedure — TIOPA 2010 s.124) | Curative — after a HMRC or foreign assessment | 24-36 months average; OECD target: 24 months | Low direct cost (HMRC fee-free); adviser fees GBP 30,000-100,000 | Eliminates double taxation on assessed period; available under almost every UK treaty |
| Bilateral APA | Preventive — agreed before transactions occur | 12-36 months negotiation; covers 3-5 future years | GBP 50,000-200,000 in adviser fees; HMRC charges no fee | Maximum certainty for recurring high-value intra-group transactions; roll-back available |
The head of tax commissions a benchmarking study using Bureau van Dijk Orbis, identifying 18 independent pharmaceutical licensors with comparable royalty rates ranging from 3.2% to 6.8% of licensee net sales. Zenith's effective rate of 18.2% falls outside the arm's-length range. Following a pre-filing meeting with HMRC Large Business, the group negotiates a bilateral APA with Irish Revenue fixing the royalty at 5.5%, eliminating enquiry risk for five years and reducing the annual UK tax exposure by GBP 22m.
⚠️Setting transfer prices without contemporaneous documentation
→ HMRC may deny the documentation defence under TIOPA 2010 s.162 if documentation was not prepared before the return was filed. Retrospective documentation prepared during an enquiry carries no statutory protection and typically weakens the taxpayer's position.
⚠️Applying TNMM without a robust, refreshed comparable search
→ Using an out-of-date or geographically mismatched comparable set invalidates the TNMM analysis. Refresh comparables every three years and apply a profit level indicator consistently with the tested party's functional profile.
⚠️Overlooking hard-to-value intangible (HTVI) rules
→ OECD BEPS Action 8 and HMRC's HTVI guidance allow authorities to look back at actual outcomes when pricing intangibles whose future income was highly uncertain at the time of transfer. Use explicit outcome-adjustment mechanisms or obtain advance clearance to manage HTVI risk.
OECD BEPS Actions 8-10 revised the Transfer Pricing Guidelines to align profits with the location of genuine value creation — principally development, enhancement, maintenance, protection, and exploitation of intangibles (the DEMPE functions). A group entity that merely holds legal title to IP but performs no DEMPE functions is entitled to only a risk-free return on its IP investment, not the full IP profit stream. UK subsidiaries that contribute to DEMPE functions (R&D employees, decision-making on commercialisation, funding risk management) are entitled to share in IP profits regardless of where legal title is held. HMRC's Large Business directorate uses DEMPE analysis to challenge offshore IP structures where UK entities perform the economically significant IP functions.
DEMPE Functions (OECD BEPS Actions 8-10)
Development, Enhancement, Maintenance, Protection, and Exploitation of intangible assets. Under the revised OECD Transfer Pricing Guidelines, legal ownership of IP alone does not entitle a group entity to the residual IP profit. Remuneration must follow the functional profile of each entity in the value chain: entities performing DEMPE functions and bearing associated risks (funded by equity capital at risk) are entitled to the residual profit; funding entities without DEMPE functions receive only a risk-free financial return. This framework is directly applied by HMRC in transfer pricing and CFC enquiries involving IP holding structures.
A robust transfer pricing framework for a UK multinational involves five operational pillars: (1) a functional analysis register mapping FAR (functions, assets, risks) to each entity; (2) a contemporaneous benchmarking file refreshed every three years; (3) Master File, Local File, and CbCR prepared within 12 months of period end for groups above GBP 586m; (4) a formal escalation process to engage HMRC Large Business pre-filing if a significant pricing change is planned; and (5) an APA strategy for the top three intra-group flows by value. Groups that invest in this framework significantly reduce both enquiry risk and potential double taxation exposure.
Estimate your UK corporation tax liability at the 25% main rate before and after a potential HMRC transfer pricing adjustment.
Open calculator →UK Head of Tax / International Tax Manager
Suggested questions
Zenith Pharma's Irish subsidiary charges a royalty rate of 18.2% of UK net sales. The TNMM benchmarking interquartile range is 3.2%–6.8% with a median of 5.0%. To what value will HMRC typically adjust the pricing on enquiry?
HMRC follows OECD guidance and adjusts to the median of the arm's-length range where the tested party falls outside the interquartile range. Adjustment to 5.0% from 18.2% on GBP 62m of royalties reduces allowable deductions by GBP 8.2m and raises UK taxable profits accordingly.
Why must transfer pricing documentation be prepared contemporaneously — before the return is filed — rather than retrospectively during an HMRC enquiry?
TIOPA 2010 s.162 provides a defence against penalties only if documentation demonstrating arm's-length pricing was in place when the return was filed. Documentation prepared retrospectively in response to an enquiry does not attract this protection.